Replies to post #1944 on PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[midastouch017]

Protalix gets FDA nod to expand product manufacturing at Carmiel site; shares ahead 6% premarket

Jun. 1, 2017 9:27 AM ET|About: Protalix BioTherapeuti... (PLX)|By: Douglas W. House, SA News Editor

Protalix BioTherapeutics (NYSEMKT:PLX) perks up 6% premarket on increased volume in response to its announcement that the FDA has approved its conversion of its Carmiel, Israel manufacturing site to a multi-product facility, thereby being able to accommodate all of its current and expected commercial and clinical needs, including Fabry candidate PRX-102.